NMRA Deadline: Rosen Law Firm Urges Neumora Therapeutics, Inc. (NASDAQ: NMRA) Stockholders with Losses to Contact the Firm for Information About Their Rights in Securities Class Action First Filed by the Firm
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Neumora Therapeutics, Inc. (
NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s September 2023 initial public offering (the “IPO”). Neumora describes itself as a “clinical-stage biopharmaceutical company.”
Important April 7, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Investors of Securities Fraud Class Action LawsuitRADNOR, PA - March 26, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (
NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025.
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRAFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Neumora To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRANEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (
NASDAQ: NMRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Neumora Therapeutics, Inc. Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (
NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (
NASDAQ: NMRA) and reminds investors of the April 7. 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Neumora Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action LawsuitRADNOR, PA - March 24, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (
NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Neumora To Contact Him Directly To Discuss Their Options
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.RADNOR, PA - March 22, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (
NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025.
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (
NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company’s Initial Public Offering (“IPO”) on September 15, 2023.
NMRA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NMRA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA)RADNOR, PA - March 20, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (
NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options
NMRA Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc. (NMRA)RADNOR, PA - March 18, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (
NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025.
NMRA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the Neumora Therapeutics, Inc. (NMRA) Class ActionSAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (
NASDAQ: NMRA) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering ("IPO") on September 15, 2023. Neumora is a clinical-stage biopharmaceutical company.
NMRA Deadline Approaching on April 7, 2025: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Class Action Lawsuit DeadlineRADNOR, PA - March 16, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (
NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options
